SCHEMBL18287259

SCHEMBL18287259

Cc1ccccc1Nc1ccc2c(c1)N(c1ccccn1)c1ccccc1C2(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 7/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ TP53 P04637 5/20 0.40
▸ TDP1 Q9NUW8 4/20 0.40
▸ HTT P42858 4/20 0.40
▸ MAPT P10636 4/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ PTK2 Q05397 5/20 0.39
▸ MAPK10 P53779 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ GFER P55789 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ GRIN2B Q13224 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ MAPK13 O15264 1/20 0.33
▸ MAPK12 P53778 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18287261 0.84 WEE1 (0.32) KMT2APTK2MEN1
SCHEMBL18290497 0.83 ALOX15 (0.44) TDP1MAPTKMT2APTK2MAPK10
SCHEMBL25089929 0.81 SMN1; SMN2 (0.44) GAASMN1; SMN2TDP1HTTMAPT
SCHEMBL17291903 0.76 SMN1; SMN2 (0.39) GAASMN1; SMN2TP53TDP1MAPT
SCHEMBL18287257 0.76 SMN1; SMN2 (0.39) GAASMN1; SMN2TP53HTTMAPT
SCHEMBL31611978 0.76 SMN1; SMN2 (0.39) GAASMN1; SMN2TP53HTTMAPT
SCHEMBL17291900 0.74 KDM4E (0.44) SMN1; SMN2TP53HTTMAPTKMT2A
SCHEMBL17525283 0.74 TP53 (0.44) GAASMN1; SMN2TP53MAPTMAPK10
SCHEMBL28617183 0.72 SMN1; SMN2 (0.37) GAASMN1; SMN2HTTMAPTKMT2A
SCHEMBL24894123 0.70 IRAK4 (0.37) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180006246-A1 TETRADENTATE METAL COMPLEXES CONTAINING INDOLOACRIDINE AND ITS ANALOGUES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2018-01-04 — — US disclosed
US-9711739-B2 Tetradentate metal complexes containing indoloacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2017-07-18 — — US disclosed
US-20160359120-A1 TETRADENTATE METAL COMPLEXES CONTAINING INDOLOACRIDINE AND ITS ANALOGUES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2016-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160359120-A1 TETRADENTATE METAL COMPLEXES CONTAINING INDOLOACRIDINE AND ITS ANALOGUES PDCD2L, AP3M1, AP3D1 GAA 4517/4885SMN1; SMN2 3478/4885TP53 475/4885
US-20180006246-A1 TETRADENTATE METAL COMPLEXES CONTAINING INDOLOACRIDINE AND ITS ANALOGUES PDCD2L, AP3M1, AP3D1 GAA 4517/4885SMN1; SMN2 3478/4885TP53 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback